Esperion Therapeutics, Inc. (ESPR)

1.9195 +0.0995 (+5.47%) As of 01:15PM EDT. Market open.

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 240

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Sheldon L. Koenig	President, CEO & Director	1.28M	N/A	1966
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer	718.86k	N/A	1972
Mr. Benjamin Halladay M.B.A.	Chief Financial Officer	N/A	N/A	1986
Mr. Glenn P. Brame	Chief Technical Operations Officer	N/A	N/A	1958
Mr. Benjamin O. Looker J.D.	General Counsel & Corporate Secretary	550.35k	N/A	1982
Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications	N/A	N/A	N/A
Ms. Betty Jean Swartz	Chief Business Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate Governance

Esperion Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 9; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.